Department of Psychiatry, Indiana University School of Medicine, 702 Barnhill Drive, Room 4300, Indianapolis, IN 46202, USA,
J Autism Dev Disord. 2010 Nov;40(11):1412-6. doi: 10.1007/s10803-010-0988-9.
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.
谷氨酸能功能障碍与脆性 X 综合征 (FXS) 的病理生理学有关。我们报告了第一个关于苯丁酸钠（一种具有潜在 mGluR5 拮抗作用的药物）在 3 名 FXS 合并自闭症成人中的试验。我们回顾了 3 名 FXS 合并自闭症障碍诊断的患者接受苯丁酸钠开放性治疗的病历。在所有 3 名患者中，苯丁酸钠均与语言交流能力的改善相关。3 名患者接受苯丁酸钠治疗的平均时间为 21.3 周。所有患者的临床总体印象-改善量表评分均显示出整体临床获益。沟通的显著改善出乎意料，这对 FXS 以及特发性自闭症的治疗具有潜在意义。
